The race to find a cure for Alzheimer's disease is intensifying, with a focus on targeting tau protein as a potential game-changer. While previous attempts to develop drugs that can target tau have failed, a new study by Biogen and partner Ionis Pharmaceuticals has shown promising results. The study, which included about 400 people with mild cognitive impairment or mild Alzheimer's, found that Biogen's experimental drug, diranersen, not only lowered tau levels but also slowed cognitive decline. This is a significant breakthrough, as it suggests that targeting tau protein could be a viable approach to treating Alzheimer's disease.
What makes this finding particularly exciting is the potential for a combination therapy. The study showed that the lowest dose of diranersen, given every six months, had a strong effect, translating to a 26% reduction in cognitive decline. This is comparable to the changes seen in earlier tests of amyloid drugs, which are currently the standard treatment for Alzheimer's. However, it's important to note that the study missed its key goal of showing that higher doses brought greater benefits, which could be a result of the counterintuitive surprise of the lowest dose having the strongest effect.
The study's findings have reignited interest and investment in tau mechanisms, which is crucial for the field of Alzheimer's research. The University of California, San Francisco, has launched a first-of-its-kind study known as the Alzheimer's Tau Platform, which will test a variety of experimental anti-tau therapies against and in combination with today's amyloid treatments. This platform approach will expand to locations around the country and include people with Alzheimer's-related protein buildup who aren't yet showing symptoms.
Additionally, researchers are exploring new ways of attacking Alzheimer's, such as an experimental cholesterol-lowering drug called obicetrapib, which may lower buildup of Alzheimer's-related proteins in people who carry a genetic risk for the disease. Companies are also trying to get Alzheimer's drugs into the brain faster and at higher volumes by penetrating the protective lining meant to protect the brain from harm. Denali Therapeutics' CEO Ryan Watts describes it as "hitching a ride" with iron that naturally gets into the brain.
In conclusion, the focus on targeting tau protein as a potential cure for Alzheimer's disease is a promising development. While there is still much to be done, the combination of new studies and innovative approaches is bringing us closer to a better understanding of Alzheimer's and the development of effective treatments.
